


The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Original) The use of a lipopeptide or lipoprotein of the structure (I)



where

R_1 and R_2 , which may be identical or different, are C_{7-25} -alkyl, C_{7-25} -alkenyl or C_{7-25} -alkynyl,

X is S, O or CH_2 ,

R_3 and R_4 are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used,

and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Inhold-Prelog rule, when X is S (sulfur),

as mucosal adjuvant in therapeutic or prophylactic vaccination via the mucous membranes.

2. (Previously presented) The use as claimed in claim 1, characterized in that the amino acid sequence Y is preferably selected from


- a) GQTNT (SEQ ID NO: 1)
- b) SKKKK (SEQ ID NO: 2)
- c) GNNDESNISFKEK (SEQ ID NO: 3) and
- d) GQTDNNSQSAAPGSGTTNT.(SEQ ID NO: 4).

3. (Previously presented) The use as claimed in claim 1, characterized in that the lipoprotein or lipopeptide of structure (I) is an S-[2, 3-bispalmitoyloxy(2R)propyl]cysteinyl-peptide, where the peptide is a physiologically tolerated amino acid sequence which consists of 12 to 25 amino acid residues and is preferably not immunogenic in the species used.

4. (Previously presented) The use as claimed in claim 1, characterized in that the mucosal adjuvant is present in a preparation with the actual vaccine component which is intended for intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral administration or administration into the milk ducts of the female breast.

5. (Previously presented) The use as claimed in claim 1, characterized in that the mucosal adjuvant is present in a kit for coadministration with a vaccine into the milk ducts of the female breast, by the intranasal, intra-NALT, aerosolized oral, intrarectal, conjunctival, intravaginal or intraurethral route.

6. (Previously presented) The use of a lipopeptide or lipoprotein of the general structure (I)



where

R₁ and R₂, which may be identical or different, are C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl or C₇₋₂₅-alkynyl, X is S, O or CH₂,

R₃ and R₄ are independently of one another H or methyl and

Y is a physiologically tolerated amino acid sequence which consists of 1 to 25, preferably 12 to 25, amino acid residues and is not immunogenic per se in the species used, and the asymmetric carbon atom marked with * as the absolute R configuration, according to the Cahn-Ingold-Prelog

rule, when X is S (sulfur), excepting an S-(2,3-diacyloxypropyl)cysteinopeptide of the sequence DhcGNNDESNI SFKEK (SEQ ID NO: 3), where N-terminally the amino acids at positions 2 and, where appropriate, 3 are absent, and/or C-terminally 1 to 2 amino acids may be deleted, as adjuvant in a non-mucosal vaccination.

7. (Previously presented) The use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is present in a preparation with at least one further adjuvant and/or antigen.

8. (Previously presented) The use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is associated or combined with a physical or biological carrier.

9. (Previously presented) The use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is administered together with one or more anti-inflammatory, antiangiogenic, cytotoxic or immunomodulatory substances or ligands or with antibodies, or is present with these in a preparation.

10. (Previously presented) The use as claimed in claim 1, characterized in that the lipopeptide or lipoprotein is present in a preparation which comprises further additives and excipients, in particular preservatives or stabilizers.

11. (Previously presented) The use as claimed in claim 1, characterized in that the vaccine which is accompanied by the adjuvant, in the form of peptides, proteins, DNA, polysaccharides, glycolipids or glucoproteins.